Phase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan

被引：0
|
作者：
Boku, N.
Yamazaki, K.
Yamamoto, N.
Takahashi, T.
Fukutomi, A.
Miyazaki, M.
Satoh, T.
Okamoto, I.
Nakagawa, K.
Fukuoka, M.
机构：
[1] Shizuoka Canc Ctr, Shizuoka, Japan
[2] Kinki Univ, Sch Med, Osaka 589, Japan
[3] Kinki Univ, Sakai Hosp, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14574
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase I clinical study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody (Nimotuzumab) in combination with chemotherapy in patients with locally-advanced breast cancer.: Preliminary results
    Soriano, J.
    Batista, N.
    Lima, M.
    Rodriguez, R.
    Lopez, M. V.
    Montenegro, A.
    Ramos, M.
    Rodriguez, L.
    Garcia, R.
    Rodriguez, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 116 - 117
  • [12] Treatment of paediatric braintumours with nimotuzumab, anti-epidermal growth factor receptor humanized monoclonal antibody.: Preliminar report
    Cabanas, Ricardo
    Saurez, Giselle
    Longchong, Martha
    Valdes, Jose
    Gonzalez, Maria C.
    Leyva, Tania
    Rios, Martha
    Herrera, Raisa
    Avila, Melba
    Infante, Mariela
    Alonso, Luis
    Fernandez, Raquel
    Piedra, Patricia
    Lage, Agustin
    Iznaga, Normando
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 523 - 524
  • [13] A phase I study of the chimeric monoclonal anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a single agent in subjects from Japan with advanced solid tumors: Safety, pharmacokinetics (PK).
    Yasui, H
    Shirao, K
    Yamamoto, N
    Shimada, Y
    Yamada, Y
    Muro, K
    Hamaguchi, T
    Boku, N
    Yoshino, T
    Saijo, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 243S - 243S
  • [14] A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers.
    Trarbach, T
    Beyer, T
    Schleucher, N
    Stattaus, J
    Mueller, SP
    Appel, D
    Tillner, J
    Schmid, KW
    Seeber, S
    Vanhoefer, U
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 199S - 199S
  • [15] A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
    Faillot, T
    Magdelenat, H
    Mady, E
    Stasiecki, P
    Fohanno, D
    Gropp, P
    Poisson, M
    Delattre, JY
    NEUROSURGERY, 1996, 39 (03) : 478 - 483
  • [16] Preclinical studies predicting low clinical toxicity of the anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) nimotuzumab
    Casaco, Angel
    Ledon, Nuris
    Iznaga-Escobar, Normando
    Elena Arteaga, Maria
    Crombet, Tania
    TOXICOLOGY LETTERS, 2008, 180 : S209 - S209
  • [17] Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor
    Vanhoefer, U
    Tewes, M
    Rojo, F
    Dirsch, O
    Schleucher, N
    Rosen, O
    Tillner, J
    Kovar, A
    Braun, AH
    Trarbach, T
    Seeber, S
    Harstrick, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 175 - 184
  • [18] A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas - Comment
    Rutka, JT
    NEUROSURGERY, 1996, 39 (03) : 483 - 483
  • [19] A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody "EMD72000 (Matuzumab)" administered weekly in Japanese patients with advanced solid tumors; safety, PIK and PD results of skin biopsies.
    Doi, T
    Ohtsu, A
    Saijo, N
    Takiuchi, H
    Ohhashi, Y
    Weber, D
    Tillner, J
    Sakata, T
    Sun, H
    Rojo, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 211S - 211S
  • [20] A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors
    Sasaki, Yasutsuna
    Miwa, Keisuke
    Yamashita, Keishi
    Sunakawa, Yu
    Shimada, Ken
    Ishida, Hiroo
    Hasegawa, Kosei
    Fujiwara, Keiichi
    Kodaira, Makoto
    Fujiwara, Yasuhiro
    Namiki, Masayuki
    Matsuda, Minami
    Takeuchi, Yutaka
    Katsumata, Noriyuki
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 332 - 340
12345